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Materials and Methods 
All reactions involving metal complexes were conducted in oven-dried glassware under a 
nitrogen atmosphere with anhydrous solvents, using standard Schlenk and glovebox techniques. 
Anhydrous solvents were obtained via elution through a solvent column drying system.1 
RuCl2(PCy3)2(=CHC6H5) was obtained from Materia, Inc. Silica gel used for the purification of 
organometallic complexes was obtained from TSI Scientific, Cambridge, MA (60 Å, pH 6.5–
7.0). NMR chemical shifts are reported in ppm downfield from Me4Si, by using the residual 
solvent peak as internal standard for 1H and 13C, and H3PO4 (δ 0.0) for 
31P. Data for NMR 
spectra are reported as follows: chemical shift (δ ppm), multiplicity, coupling constant (Hz) and 
integration. IR spectra were recorded on a Perkin-Elmer Paragon 1000 Spectrophotometer. Gas 
chromatography data was obtained using an Agilent 6850 FID gas chromatograph equipped with 
a DB-Wax Polyethylene Glycol capillary column (J&W Scientific). X-ray crystallographic 
structures were obtained by the Beckman Institute X-ray Crystallography Laboratory of the 
California Institute of Technology. Crystallographic data have been deposited at the CCDC, 12 
Union Road, Cambridge CB2 1EZ, U.K., and copies can be obtained on request, free of charge, 
by quoting the publication citation and the deposition numbers 651006 (13) and 678270 (19). 
The screening of the catalysts, in ring-closing metathesis (RCM), cross metathesis (CM), and 
ring-opening metathesis polymerization reactions (ROMP), was conducted according to 
literature procedures.2
 
The initiation kinetics studies were conducted according to literature 
procedures.3 
 
 
 
 
 
 
 
 
                                                
1 Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15,  
1518–1520. 
2 Ritter, T.; Hejl, A.; Wenzel, A. G.; Funk, T. W.; Grubbs, R. H. Organometallics 2006, 25, 5740-5745. 
3 Sanford, M. S.; Love, J. A.; Grubbs, R. H. J. Am. Chem. Soc. 2001, 123, 6543-6554. 
S–3 
 
Experimental 
4,4,5,5-Tetramethyl-1,3-diphenyl-4,5-dihydro-1H-imidazol-3-ium chloride (10) 
Diamine 94 (2.07 g, 7.72 mmol) was dissolved in diethyl ether (20 ml) 
and treated with a solution of hydrogen chloride (4 M in dioxane, 7.7 
ml) to precipitate the diamine hydrochloride salt. The white solid was 
collected by filtration and washed with copious amount of diethyl 
ether. The solid was placed in a flask and added triethyl orthoformate (25 ml). The resulting 
mixture was stirred at 130 °C for 10 min then cooled. After cooling to room temperature, the 
white solid was collected by filtration washing with large amount of diethyl ether and then with 
acetone to give the desired imidazolidinium chloride salt 10 (1.91 g, 6.07 mmol, Y = 79%). 
1H NMR (300 MHz, CD2Cl2): δ 9.37 (s, 1H), 7.69-7.66 (m, 4H), 7.54-7.52 (m, 6H), 1.46 (s, 
12H). 13C NMR (75 MHz, CD2Cl2): δ 156.8, 133.3, 130.4, 130.0, 128.6, 74.0, 21.5. IR: 3015 
(m), 2981 (m), 1616 (s), 1585 (s), 1491 (s), 1455 (s), 1390 (m), 1292 (m), 1269 (s), 1154 (s), 
1078 (w), 782 (m), 768 (m), 701 (s).  HRMS Calc'd for C19H23N2: 279.1861. Meas: 279.1852. 
 
RuCl2(4,4,5,5-Tetramethyl-1,3-diphenylimidazolin-2-ylidene)(=CH–Ph)(PCy3) (12) 
A mixture of 10 (288 mg, 0.915 mmol) and dry benzene (20 ml) was 
added KHMDS (182 mg, 0.915 mmol) under nitrogen atmosphere, and 
the resulting mixture was stirred at room temperature for 15 minutes, 
after which time, RuCl2(PCy3)2(=CHC6H5) (500 mg, 0.608 mmol) was 
added in one portion. After stirred at room temperature for overnight, 
the reaction mixture was concentrated under vacuum. The dark brown 
residue was added dry hexane (10 ml), and the mixture was stirred at room temperature for 20 
minutes. The brown precipitation was collected by filtration and washed with hexane and then 
with methanol to give the desired ruthenium complex 12 (275 mg, 0.335 mmol, Y = 55%). Full 
characterization of 12 was difficult due to its instability. 
1H NMR (500 MHz, C6D6): δ 19.61 (d, J = 3.8 Hz, 1H), 8.11 (d, J = 6.7 Hz, 2H), 7.36-6.67 (m, 
13H), 2.25-2.18 (m, 3H), 1.68-1.54 (m, 15H), 1.34-1.25 (m, 6H), 1.17-1.06 (m, 9H), 0.87 (s, 
6H), 0.85 (s, 6H). 13C NMR (125 MHz, C6D6): δ 300.8, 217.2, 216.6, 151.8, 139.3, 137.9, 133.9, 
                                                
4 Garry, M. Ann Chim France 1942, 17, 5-99. 
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131.1, 129.5, 129.4, 129.2, 129.1, 128.9, 128.7, 128.5, 128.3, 128.0, 127.8, 127.7, 70.8, 70.7, 
70.5, 33.4, 33.3, 29.6, 28.5, 28.4, 27.1, 22.5, 22.0. 31P NMR (121 MHz, C6D6): δ 22.35. 
 
RuCl2(4,4,5,5-Tetramethyl-1,3-diphenylimidazolin-2-ylidene)(=CH–o-iPrPh) (13) 
A mixture of 12 (200 mg, 0.240 mmol), o-isopropoxy-β-
methylstyrene (14) (64 mg, 0.365 mmol), and p-toluenesulfonic acid 
(51 mg, 0.268 mmol) in benzene was stirred at 40 °C for 1 hour. After 
cooled to room temperature, the mixture was evaporated under 
vacuum and the residue was washed with methanol. The green solid 
thus obtained was recrystallized from benzene/n-pentane to give 13 as 
a dark green, crystalline solid (65 mg, 0.109 mmol, Y = 45%). X-ray quality crystal was obtained 
by a slow diffusion of pentane into a benzene solution. 
1H NMR (500 MHz, C6D6): δ 16.62 (s, 1H), 8.27 (d, J = 7.5 Hz, 2H), 7.56 (d, J = 7.1 Hz, 2H), 
7.42 (t, J = 7.7 Hz, 2H), 7.26 (t, J = 7.3 Hz, 1H), 7.17-7.03 (m, 4H), 6.96 (dd, J = 7.5, 1.6 Hz, 
1H), 6.66 (t, J = 7.3 Hz, 1H), 6.38 (d, J = 8.3 Hz, 1H), 4.49 (sept, J = 6.2 Hz, 1H), 1.38 (d, J = 
6.2 Hz, 6H), 0.97 (s, 6H), 0.91 (s, 6H). 13C NMR (125 MHz, CD2Cl2): δ 296.1 (d, JC–H = 22 Hz), 
208.0, 152.8, 144.0, 140.5, 138.7, 132.5, 131.4, 130.4, 129.7, 129.2, 129.2, 128.9, 128.5, 
128.5(4), 128.5(3), 128.4(8), 122.6, 121.8, 113.2, 75.0, 71.5, 70.3, 22.3, 22.2, 21.8, 21.7. IR: 
3062 (w), 2979 (m), 2935 (w), 1589 (m), 1494 (s), 1453 (m), 1396 (s), 1370 (s), 1289 (m), 1267 
(s), 1152 (s), 1114 (m), 954 (m), 938 (m), 844 (w), 808 (w), 770 (m), 748 (m), 714 (s) cm-1.  
HRMS Calc'd for C29H34Cl2N2ORu: 598.1092. Meas: 598.1070. 
 
 
N-Mesityl-2-methyl-2-(phenylamino)propanamide (15) 
2-bromo-2-methylpropanoyl bromide (4.50 g, 19.57 mmol) was 
added to a mixture of 2,4,6-trimethylaniline (2.41g, 17.78 mmol), 
triethylamine (3.60 g, 35.56 mmol), and CH2Cl2 (20 ml) at 0 °C 
under Ar atmosphere. The cooling bath was removed after the 
addition was completed, and the reaction mixture was stirred at 
room temperature for 1.5 hour, after which time the mixture was diluted with CH2Cl2 (20 ml) 
and added aqueous solution of NH4Cl. After the aqueous phase was separated, the organic layer 
was washed with brine and dried over anhydrous MgSO4. Filtration and concentration of the 
Cl2Ru
O
iPr
N N
13
O
HNNH
15
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filtrate gave 2-bromo-N-mesityl-2-methylpropanamide as a pale yellow solid (5.05g, 17.78 
mmol, 100%). A solution of this amide (284 mg, 1.00 mmol) in dry THF (5 ml) was added to a 
mixture of sodium hydride (60% in mineral oil, 80 mg, 2.00 mmol), aniline (112 mg, 1.20 mmol) 
and THF (5 ml), and the resulting mixture was stirred for overnight at room temperature. The 
mixture was then added an aqueous solution of NH4Cl (15 ml), extracted with ethyl acetate (20 
ml × 2), and the combined organic layer was washed with brine then dried over anhydrous 
Na2SO4. After filtration, the filtrate was concentrated under vacuum, and the residue was purified 
by column chromatography on silica (eluent: Hexane/Ethyl acetate = 5/1 ~ 4/1) to give 15 as a 
white solid (255 mg, 0.86 mmol, Y = 86%). 
1H NMR (300 MHz, CDCl3): δ 8.35 (s, 1H), 7.25-7.17 (m, 2H), 6.84-6.71 (m, 5H), 3.98 (s, 1H), 
2.23 (s, 3H), 2.11 (s, 6H), 1.63 (s, 6H). 13C NMR (75 MHz, CDCl3): δ 173.8, 144.5, 136.4, 
134.8, 131.0, 129.0, 119.2, 116.2, 58.4, 26.2, 20.8, 18.6. IR: 3341 (m), 3310 (s), 2987 (w), 1666 
(s), 1607 (m), 1488 (s), 1376 (m), 1318 (m), 1264 (m), 1210 (m), 1162 (m), 850 (m), 749 (s), 
696 (m) cm-1. HRMS Calc'd for C19H24N2O: 297.1967. Meas: 297.1956. 
 
1-Mesityl-4,4-dimethyl-3-phenyl-4,5-dihydro-1H-imidazol-3-ium chloride (16) 
A solution of 15 (100 mg, 0.337 mmol) in dry dimethoxyethane (2 
ml) was added lithium aluminum hydride (80 mg, 2.1 mmol), and the 
mixture was refluxed for 1 day. After cooling to room temperature, 
the reaction was quenched by adding H2O (0.08 ml), 15% aqueous 
NaOH (0.08 ml), and H2O (0.24 ml) successively. The white precipitation was filtered off and 
the filtrate was purified by column chromatography on silica (eluent: Hexane/Ethyl acetate = 
10/1) to give N1-mesityl-2-methyl-N2-phenylpropane-1,2-diamine as a pale yellow solid (54 mg, 
0.192 mmol, Y = 57%). The diamine (1.45 g, 5.14 mmol) was converted to the corresponding 
dihydrochloride salt (1.83 g, 5.14 mmol, 100%) by treating with HCl solution (4 M in dioxane). 
A mixture of this salt (500 mg, 1.4 mmol) and triethyl orthoformate (4.7 ml) was stirred at 130 
°C for 5 min then cooled. After cooling to room temperature, the white precipitation was 
collected by filtration washing with large amount of diethyl ether and then with acetone to give 
the desired imidazolidinium chloride salt 16 (367 mg, 1.12 mmol, Y = 80%). 
1H NMR (300 MHz, CDCl3): δ 9.76 (s, 1H), 7.65-7.62 (m, 2H), 7.49-7.47 (m, 3H), 6.92 (s, 2H), 
4.13 (s, 2H), 2.39 (s, 6H), 2.27 (s, 3H), 1.69 (s, 6H). 13C NMR (75 MHz, CDCl3): δ 158.4, 140.2, 
N N
Cl
16
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134.9, 132.3, 130.2, 130.0, 129.9, 129.8, 127.4, 68.6, 63.7, 26.7, 20.9, 18.1. IR: 3401 (m), 2975 
(w), 1624 (s), 1592 (m), 1301 (w), 1263 (m), 1219 (m), 856 (w), 776 (w) cm-1. HRMS Calc'd for 
C20H25N2: 293.2018. Meas: 293.2021. 
 
RuCl2(1-Mesityl-4,4-dimethyl-3-phenylimidazolin-2-ylidene)(=CH–Ph)(PCy3) (18) and 
RuCl2(1-Mesityl-4,4-dimethyl-3-phenylimidazolin-2-ylidene)(=CH–o-iPrPh) (19) 
The phosphine complex 18 and the phosphine-free complex 19 was prepared from 16 
according to the procedure described for the synthesis of 13. X-ray quality crystal of 19 was 
obtained by a slow diffusion of pentane into a CH2Cl2 solution. 
1H NMR (500 MHz, CD2Cl2): δ 19.14 (s, 1H), 8.77 (br s, 1H), 
7.89-7.87 (m, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.44 (tt, J = 7.4, 1.2 
Hz, 1H), 7.39 (t, J = 7.4 Hz, 1H), 7.10 (t, J = 7.6 Hz, 2H), 6.71 (br 
s, 2H), 5.84 (br s, 1H), 3.66 (br s, 2H), 2.65-1.99 (m, 5H), 1.91 (s, 
3H), 1.94-1.87 (m, 3H), 1.53-1.47 (m, 9H), 1.36 (s, 6H), 1.39-1.23 
(m, 6H), 0.98-0.89 (m, 16H). 13C NMR (125 MHz, CD2Cl2): δ 
296.8, 218.1, 217.5, 151.8, 138.3, 137.7, 136.9, 136.1, 135.0, 129.7, 129.4, 129.1, 128.9, 128.6, 
128.2, 65.9, 65.2, 32.7, 32.5, 29.2, 28.3, 28.2, 27.7, 26.7, 21.2, 18.8. IR (CD2Cl2): 2931 (s), 2852 
(m), 1987 (w), 1487 (m), 1447 (m), 1400 (m), 1301 (m), 1175 (m), 778 (w) cm-1. HRMS Calc'd 
for C45H63Cl2N2PRu: 834.3150. Meas: 834.3165. 
 
1H NMR (500 MHz, C6D6): δ 16.49 (s, 0.5H), 16.48 (s, 0.5H), 
7.99-7.96 (m, 2H), 7.57-7.49 (m, 4H), 7.10 (d, J = 0.6 Hz, 2H), 
6.91 (d, J = 4.4 Hz, 2H), 6.86 (d, J = 8.1 Hz, 1H), 4.90 (sept, J = 
6.2 Hz, 1H), 3.91 (s, 2H), 2.46 (s, 3H), 2.33 (s, 6H), 1.47 (s, 6H), 
1.22 (d, J = 6.2 Hz, 6H). 13C NMR (125 MHz, CD2Cl2): δ 297.6 
(d, JC–H = 18 Hz), 209.9, 152.6, 145.1, 139.4, 138.8, 138.1, 136.5, 
135.6, 130.1, 1230.0, 129.4, 128.9(0), 128.8(6), 122.9, 122.5, 
113.4, 75.4, 66.0, 65.5, 27.8, 21.8, 21.5, 18.5. IR: 2967 (m), 1589 (m), 1572 (m), 1489 (m), 1472 
(m), 1450 (m), 1380 (s), 1317 (m), 1286 (s), 1207 (m), 1179 (m), 1154 (m), 1113 (s), 1031 (w), 
931 (m), 877 (w), 805 (w), 770 (w), 754 (m), 699 (m) cm-1. HRMS Calc'd for C34H44Cl2N2ORu: 
612.1249. Meas: 612. 1229. 
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RhCl(CO)2(4,4,5,5-Tetramethyl-1,3-diphenylimidazolin-2-ylidene) (32a) 
The imidazolidinium salt 16 (33 mg, 0.10 mmol), KHMDS (20 mg, 
0.10 mmol), and toluene (2 ml) was stirred at room temperature under 
N2 for 15 min, and added to a suspension of [RhCl(COD)]2 (20 mg, 
0.04 mmol) in toluene (1 ml). The resulting mixture was stirred at room 
temperature for 1.5 hour, and then the solvent was removed under 
vacuum. The residue was purified by column chromatography on TSI 
silica (eluent: 2% EtOH in CH2Cl2) to give [(NHC)RhCl(COD)] 31a as a yellow powder. A 
solution of 31a in CH2Cl2 (3 ml) was bubbled with CO for 1 hour. The mixture was then 
concentrated under vacuum and the residue was washed with dry hexane (2 ml × 3). The 
resulting solid was dried under vacuum to give 32 (26 mg, 0.055 mmol, Y = 76% two steps). 
1H NMR (500 MHz, CD2Cl2): δ 7.49-7.36 (m, 10H), 1.28 (s, 6H), 1.27 (s, 6H). 13C NMR (125 
MHz, CD2Cl2): δ 202.8 (JC–Rh = 40 Hz), 187.0 (JC–Rh = 54 Hz), 183.6 (JC–Rh = 76 Hz), 138.3, 
131.7, 129.3, 129.1, 128.9, 72.1, 22.0, 21.9. IR (CD2Cl2): 2078, 1996 cm-1. HRMS Calc'd for 
C21H22ClN2O2Rh: 472.0425. Meas: 472.0402. 
 
RhCl(CO)2(1-Mesityl-4,4-dimethyl-3-phenylimidazolin-2-ylidene) (32b) 
The imidazolidinium 16 (33 mg, 0.10 mmol) was treated as 
described above to give 32b (32 mg, 0.066 mmol, Y = 94% two 
steps). 
1H NMR (500 MHz, CD2Cl2): δ 7.49-7.47 (m, 4H), 7.36 (s, 1H), 
6.98 (br s, 2H), 3.77 (br s, 2H), 2.42 (br s, 6H), 2.33 (s, 3H), 1.46 (s, 
6H). 13C NMR (125 MHz, CD2Cl2): δ 204.4 (JC–Rh = 40 Hz), 186.5 
(JC–Rh = 54 Hz), 183.8 (JC–Rh = 75 Hz), 139.2, 137.8, 135.5, 131.7, 129.9, 129.2, 129.1, 128.9, 
67.3, 65.4, 27.6, 21.4. IR (CD2Cl2): 2079, 1996 cm-1. HRMS Calc'd for C22H24N2O2Rh: 
451.0893. Meas: 451.0889. 
N N
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Cl CO
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Standard Activity Test: RCM Reactions 
All tests were performed according to the experimental procedure described by Ritter et al.1  
 
EtO2C CO2Et EtO2C CO2Et
catalyst (1 mol%)
 
At 30 °C, CD2Cl2 (0.1 M) 
 
 
At 60 °C, C6D6 (0.1 M) 
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EtO2C CO2Et EtO2C CO2Et
catalyst (1 mol%)
CD2Cl2 (0.1 M), 30 °C
22 23  
 
At 30 °C, CD2Cl2 (0.1 M) 
 
 
At 60 °C, C6D6 (0.1 M) 
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EtO2C CO2Et EtO2C CO2Etcatalyst (5 mol%)
24 25  
 
At 30 °C, CD2Cl2 (0.1 M) 
 
 
At 60 °C, C6D6 (0.1 M) 
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CM Reactions 
 
Ph OAcAcO Ph
OAc
catalyst (2.5 mol%)
CD2Cl2 (0.2 M), 25 °C
+
26 27 28 (E/Z)  
 
 
 
ROMP of Cyclooctadiene 
catalyst (0.1 mol%)
CD2Cl2 (0.5 M), 30 °C
n
29 30  
 
 
S–12 
Initiation Studies 
The initiation kinetics studies of compound 13 were conducted according to literature 
procedures.2 
Cl2Ru
O
iPr
N N
13
OnBu
Cl2Ru
N N
OnBu
 
 
(303 K) 13 2 
ΔH‡ (kcal/mol) 11.9 (± 1.7) 15.2 (± 0.8) 
ΔS‡ (e.u.) –30 (± 6) –19 (± 3) 
ΔG‡ (kcal/mol) 21.0 (± 0.1) 20.7 (± 0.01) 
kinit 47 × 10–4 67 × 10–4 
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NMR Spectra 
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13C-NMR of 12 
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31P-NMR of 12 
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1H-NMR of 13 
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13C-NMR of 13 
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1H-NMR of 18 
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31P-NMR of 18 
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1H-NMR of 19 
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13C-NMR of 19 
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1H-NMR of 32a 
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13C-NMR of 32a 
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1H-NMR of 32b 
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13C-NMR of 32b 
 
 
 
N
N
R
h
C
O
C
l
C
O
3
2
b
S–26 
X-Ray Structural Analysis 
 
Minimum Overlap View of 13 
 
 
Selected Bond Lengths [Å] and Angles [°] for 13 
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Minimum Overlap View of 19 
 
 
Selected Bond Lengths [Å] and Angles [°] for 19 
 
